Genetic Testing for Ovarian Cancer Risk: What You Need to Know
Ovarian cancer is one of the most challenging cancers to detect early and treat effectively, partly due to its subtle symptoms and late-stage diagnosis. However, with advances in genetic testing, women with a family history of ovarian or related cancers now have the opportunity to assess their risk and take preventive measures. Genetic testing for ovarian cancer can provide valuable insights into a woman's risk, enabling informed decisions about monitoring, prevention, and treatment options. This article explores the role of genetic testing in ovarian cancer, what it involves, and how it can help women at risk.
Genetic testing for ovarian cancer is a process that examines a woman’s DNA for specific inherited mutations that increase the risk of developing ovarian cancer. While most cases of ovarian cancer are sporadic and occur by chance, about 10-15% of ovarian cancer cases are linked to inherited genetic mutations. These mutations are usually passed down from parents and can significantly increase the likelihood of developing ovarian cancer, as well as other cancers, such as breast cancer.
Several inherited genetic mutations have been identified that can increase the risk of ovarian cancer. The most well-known are BRCA1 and BRCA2, but there are other mutations and conditions that also raise the risk.
The BRCA1 and BRCA2 genes are tumor suppressor genes that help repair damaged DNA. When these genes are mutated, the body's ability to repair DNA is compromised, leading to an increased risk of cancers like breast, ovarian, prostate, and pancreatic cancer. Women with mutations in these genes have a significantly higher risk of developing ovarian cancer, with lifetime risks ranging from 15% to 45% for BRCA1 and 10% to 20% for BRCA2, compared to a general population risk of about 1.3%.
BRCA mutations can be inherited from either the mother or the father, and women who carry these mutations often have a family history of breast or ovarian cancer. Genetic testing for BRCA1 and BRCA2 mutations can help identify women at high risk, enabling early surveillance, preventive measures, and personalized treatment plans.
Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is another genetic condition that increases the risk of ovarian cancer. Lynch syndrome is caused by mutations in genes responsible for DNA mismatch repair, including MLH1, MSH2, MSH6, and PMS2. These mutations also increase the risk of colorectal, endometrial, and other cancers.
Women with Lynch syndrome have a 10% to 15% lifetime risk of developing ovarian cancer, in addition to their increased risk of endometrial (uterine) cancer and colorectal cancer. Genetic testing for Lynch syndrome can help identify women who may benefit from enhanced screening and preventive measures.
There are other less common genetic mutations that may also increase the risk of ovarian cancer, including:
RAD51C and RAD51D: Mutations in these genes are linked to a moderate increase in ovarian cancer risk.
BRIP1: This gene, involved in DNA repair, is associated with an increased risk of ovarian cancer, particularly for women with a family history of the disease.
PALB2: Similar to BRCA1 and BRCA2, PALB2 mutations are associated with an increased risk of ovarian and breast cancers.
Although these mutations are rarer than BRCA1 and BRCA2, genetic testing can help identify individuals who may carry them and assess their risk.
Genetic testing for ovarian cancer risk is especially important for women with certain characteristics or family histories that suggest they may be at higher risk. The following groups may benefit most from genetic testing:
Women with close relatives (mother, sister, or daughter) who have been diagnosed with ovarian cancer, breast cancer, or other cancers associated with hereditary conditions (like Lynch syndrome) are at higher risk for carrying inherited genetic mutations. If multiple family members have been diagnosed with cancer, especially at a young age, genetic testing is recommended.
Women with a personal history of breast cancer, particularly those diagnosed at a young age (under 50), may be at higher risk for ovarian cancer if they carry a BRCA1 or BRCA2 mutation. If a woman has been diagnosed with both breast and ovarian cancer, genetic testing is highly recommended.
Certain ethnic groups have a higher prevalence of genetic mutations that increase ovarian cancer risk. For example, Ashkenazi Jewish women are more likely to carry BRCA1 or BRCA2 mutations, with studies showing that about 1 in 40 women of Ashkenazi Jewish descent carry a BRCA mutation. Women of Eastern European Jewish descent, as well as some Scandinavian populations, also have an increased frequency of these mutations.
If a woman knows that a family member has tested positive for a BRCA1, BRCA2, or Lynch syndrome mutation, it’s advisable for her to undergo genetic testing to understand her own risk. Identifying whether the mutation is present can help guide her treatment and prevention decisions.
Genetic testing for ovarian cancer typically involves a blood test or a saliva sample to analyze DNA for specific genetic mutations. The process generally includes the following steps:
Genetic Counseling: Before undergoing genetic testing, women are often advised to meet with a genetic counselor. This professional will help assess family history, discuss the potential outcomes of testing, and explain the psychological and medical implications of the results.
Sample Collection: A blood sample or saliva sample is collected from the patient. The sample is then sent to a lab for analysis.
Genetic Analysis: The laboratory tests the sample for specific mutations in the BRCA1, BRCA2, and other related genes associated with ovarian cancer. Results typically take a few weeks to process.
Results and Follow-Up: The results are reviewed with a genetic counselor or physician. If a mutation is found, the healthcare provider will discuss the potential risks, preventive measures, and monitoring options available. If no mutation is found, the risk of ovarian cancer may be considered to be similar to the general population.
The results of genetic testing for ovarian cancer can have a significant impact on a woman’s health decisions. If a high-risk mutation, such as BRCA1 or BRCA2, is found, the following options may be discussed:
Increased Surveillance: Women with a BRCA1 or BRCA2 mutation may begin earlier and more frequent screenings for ovarian cancer, such as transvaginal ultrasounds and CA-125 blood tests, starting in their 30s or 40s.
Preventive Surgery: Women with a high genetic risk may choose to undergo preventive measures such as prophylactic oophorectomy (removal of the ovaries) and salpingectomy (removal of the fallopian tubes), particularly after completing their childbearing years. This can significantly reduce the risk of ovarian cancer, although it is not a guarantee.
Chemoprevention: Some women with BRCA mutations may consider chemoprevention strategies, such as taking oral contraceptives, which have been shown to lower ovarian cancer risk in high-risk women.
Personalized Treatment Plans: If ovarian cancer is diagnosed, the results of genetic testing can guide treatment decisions, such as the use of PARP inhibitors (e.g., olaparib) or other targeted therapies that are particularly effective in BRCA-mutated cancers.
Genetic testing for ovarian cancer provides a powerful tool for assessing risk and guiding prevention and treatment decisions. With the identification of high-risk genetic mutations like BRCA1, BRCA2, and Lynch syndrome, women can take proactive steps to monitor their health, reduce their risk, and make informed decisions about preventive measures such as surgery or increased surveillance.
Genetic testing is not only beneficial for women with a family history of cancer, but it is also an empowering tool for those looking to understand their individual cancer risk. By consulting with a healthcare provider and genetic counselor, women can gain a clearer understanding of their genetic risks and make choices that can significantly impact their health and well-being.
